


Healthcare Industry News: HIV/AIDS
News Release - September 18, 2007
ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
Source: Merck
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
